Therefore, it can be hypothesized that in patients with BRAF mutation with ZEB1-low and whose cancer cells are exposed to a microenvironment with high competition for nutrients (e.g., CSM1; ref. 74), the increase in non–TGF-β/EMT and glycolysis/OXPHOS leads to a metabolic rewiring and poorer survival. The gene discussed is BRAF; the disease is cancer.